Therapeutic Solutions International Launches VasoSome Vascular Inc Based on Successful Treatment of Aortic Aneurysms using Patent Pending Exosome Therapy
Clinical Stage Company Expands Regenerative Medicine Franchise into 4 billion Dollar Aneurysm Market
ELK CITY, Idaho–(BUSINESS WIRE)–Therapeutic Solutions International (TSOI) announced formation of a new spin-off company, VasoSome Vascular Inc, focused on treating the “living timebomb” condition of aortic aneurysms using stem cell derived exosomes.
The aorta is the body’s main artery, carrying blood from the heart up to the head and down to the other major organs. An aortic aneurysm is a balloon-like bulge in the aorta that in many cases continues to grow. The larger its diameter, the more likely it is that it will burst, which is associated with fatality. The results announced today, for which a patent was filed, demonstrate administration of stem cell derived exosomes suppress growth of aortic aneurysms in an animal model.
“Aortic aneurysms affect an estimated at 1.3–8.9% of men and 1.0–2.2% of women. Of these, a significant portion are ineligible for surgical or endovascular approaches. The basis of VasoSome Vascular is to utilize stem cell exosomes to stabilize and possibly even reverse growth of aortic aneurysms,” said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. “Based on our clinical experiences using JadiCells and other stem cell products, I am confident as a physician that the field of aortic aneurysms is a relatively wide-open space for application of regenerative medicine. I am excited to assist the new company in advancing its initial milestones.”
VasoSome Vascular is currently performing Investigational New Drug (IND)-enabling studies and hopes to file with the FDA by the end of 2023 to initiate a Phase I/II clinical trial.
“We are excited to be commercializing the utilization of these nanoparticles called ‘exosomes’ in overcoming limitations of existing stem cell therapies to diffuse the ‘living time bomb’ known as aortic aneurysms,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International. “By leveraging the potency of our regenerative medicine base, we are grateful to be able to generate so many new companies across diverse areas of biology in order to advance patient treatments and augment shareholder value to the highest extent possible.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company’s corporate website is www.therapeuticsolutionsint.com.